Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of RAPT Therapeutics, Inc. (RAPT) Investigation

Published March 17, 2023

NEW YORK, NY / ACCESSWIRE / March 17, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. ("Rapt" or the "Company") (NASDAQ:RAPT). Investors who purchased Rapt securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site:

Bronstein, Gewirtz and Grossman, LLC, Friday, March 17, 2023, Press release picture

The investigation concerns whether Rapt has violated federal securities laws.

On March 14, 2023, Rapt issued a press release in which the Company disclosed, among other items, that "[f]or our Phase 2b trial of RPT193 in atopic dermatitis, we now expect topline results in mid-2024 due to recent slower than expected patient enrollment as we did not see the seasonal uptick that we anticipated." On news of the delay, Rapt's stock price fell $5.00 per share, or 20.24%, to close at $19.70 per share on March 14, 2023.

If you are aware of any facts relating to this investigation or purchasedRapt shares, you can assist this investigation by visiting the firm's site: can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 |

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View source version on


News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.